Barclays Maintains Overweight on Sutro Biopharma, Raises Price Target to $57

Benzinga · 19h ago
Barclays analyst Lukas Shumway maintains Sutro Biopharma (NASDAQ:STRO) with a Overweight and raises the price target from $56 to $57.